1.14

6.54% 0.07

Pre-market: 1.13 -0.01 -0.88%

Galmed Pharmaceuticals Ltd (GLMD)

Overview News Price History Why GLMD Down? Discussions Forecast Stock Split

Galmed Pharmaceuticals Ltd stock is traded at $1.14, with a volume of 333.87K. It is up +6.54% in the last 24 hours and down -4.22% over the past month. Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Previous Close:

$1.07

Open:

$1.11

24h Volume:

333.87K

Relative Volume:

0.17

Market Cap:

$6.25M

Revenue:

Net Income/Loss:

$-8.72M

P/E Ratio:

-0.2078

EPS:

-5.4871

Net Cash Flow:

$-5.47M

1W Performance:

+23.40%

1M Performance:

-4.22%

6M Performance:

-24.50%

1Y Performance:

-58.70%

1-Day Range:

$1.03

$1.15

1-Week Range:

$0.884

$1.15

52-Week Range:

$0.7449

$3.61

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name

Galmed Pharmaceuticals Ltd

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

Address

Employee

Twitter

@GalmedPharma

Next Earnings Date

2025-08-19

Latest SEC Filings

GLMD's Discussions on Twitter

Compare GLMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLMD Galmed Pharmaceuticals Ltd	1.14	5.86M	0	-8.72M	-5.47M	-5.4871
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-20	Downgrade	B. Riley FBR	Buy → Neutral
Feb-04-20	Initiated	Craig Hallum	Buy
Jan-30-20	Resumed	Cantor Fitzgerald	Overweight
Dec-02-19	Initiated	Canaccord Genuity	Buy
Dec-12-18	Initiated	B. Riley FBR	Buy
Aug-02-18	Reiterated	Maxim Group	Buy
Jul-13-18	Initiated	Stifel	Buy
Jul-12-18	Initiated	Cantor Fitzgerald	Overweight
Jun-12-18	Reiterated	H.C. Wainwright	Buy
Mar-15-18	Upgrade	Maxim Group	Hold → Buy
Feb-14-18	Downgrade	Maxim Group	Buy → Hold
Feb-12-18	Reiterated	H.C. Wainwright	Buy
Nov-15-17	Initiated	ROTH Capital	Buy
Aug-08-17	Reiterated	H.C. Wainwright	Buy
Jul-31-17	Reiterated	Maxim Group	Buy
Aug-01-16	Reiterated	Maxim Group	Buy
Jul-06-16	Resumed	ROTH Capital	Buy
Mar-28-16	Resumed	H.C. Wainwright	Buy
Jun-23-15	Initiated	H.C. Wainwright	Buy
May-06-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News

Dec 04, 2025

Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsWeekly Loss Report & Daily Momentum Trading Reports - Newser

Dec 04, 2025

Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com

Dec 04, 2025

Galmed stock rises after patent grant for MASH combo therapy - Investing.com India

Dec 04, 2025

Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Australia

Dec 04, 2025

Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks

Dec 04, 2025

Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com

Dec 04, 2025

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - WV News

Dec 04, 2025

Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser

Dec 04, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Dec 04, 2025

Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser

Dec 04, 2025

Dec 03, 2025

Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser

Dec 03, 2025

Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser

Dec 03, 2025

Dec 02, 2025

Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN

Dec 02, 2025

Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser

Dec 02, 2025

Dec 01, 2025

Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria

Dec 01, 2025

Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria

Dec 01, 2025

Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com

Dec 01, 2025

Galmed reports $19.2 million cash position, advances Aramchol programs - Investing.com

Dec 01, 2025

Galmed Issues CEO Letter to Shareholders - Sahm

Dec 01, 2025

What drives Galmed Pharmaceuticals Ltd stock priceEx-Dividend Date Alerts & Fast Growing Portfolio Trading - earlytimes.in

Dec 01, 2025

Nov 29, 2025

Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Quarterly Trade Report & Consistent Profit Trading Strategies - BỘ NỘI VỤ

Nov 29, 2025

Energy Moves: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - moha.gov.vn

Nov 29, 2025

Nov 27, 2025

EV Market: How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Action & Fast Gaining Stock Reports - BỘ NỘI VỤ

Nov 27, 2025